Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C, Marzocchi G, Santoro A, Cavo M. Zannetti BA, et al. Among authors: tacchetti p. Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035. Am J Hematol. 2015. PMID: 25858483 Free article.
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, de Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M; Bologna 2002 study. Cavo M, et al. Among authors: tacchetti p. Blood. 2005 Jul 1;106(1):35-9. doi: 10.1182/blood-2005-02-0522. Epub 2005 Mar 10. Blood. 2005. PMID: 15761019 Free article.
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.
Cavo M, Terragna C, Renzulli M, Zamagni E, Tosi P, Testoni N, Nicci C, Cangini D, Tacchetti P, Grafone T, Cellini C, Ceccolini M, Perrone G, Martinelli G, Baccarani M, Guardigni L. Cavo M, et al. Among authors: tacchetti p. J Clin Oncol. 2006 Jan 20;24(3):e4-5. doi: 10.1200/JCO.2005.04.7506. J Clin Oncol. 2006. PMID: 16421414 No abstract available.
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G, Ceccolini M, Boni P, Tura S, Baccarani M, Cavo M. Tosi P, et al. Among authors: tacchetti p. Eur J Haematol. 2006 May;76(5):399-404. doi: 10.1111/j.0902-4441.2005.t01-1-EJH2520.x. Epub 2006 Feb 15. Eur J Haematol. 2006. PMID: 16480429 Clinical Trial.
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L, D'Arco A, Ronconi S, Cellini C, Offidani M, Perrone G, Ceccolini M, Brioli A, Tura S, Baccarani M, Cavo M. Tosi P, et al. Among authors: tacchetti p. Blood. 2006 Dec 1;108(12):3951-2. doi: 10.1182/blood-2006-07-033571. Blood. 2006. PMID: 17114572 Free article. Clinical Trial. No abstract available.
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M. Zamagni E, et al. Among authors: tacchetti p. Haematologica. 2007 Jan;92(1):50-5. doi: 10.3324/haematol.10554. Haematologica. 2007. PMID: 17229635 Free article.
111 results